MissionIR Articles
-
Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million
Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and…
-
Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine
Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ).…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research…
-
Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients Helomics has pioneered testing of…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for…
-
MissionIRNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”)…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to…
-
MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders
Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry.…
-
Predictive Oncology (NASDAQ: POAI) Adjourns Special Virtual Meeting; CEO Requesting Shareholder Vote for Critical Tax-Related Proposal
POAI sent letter to shareholders requesting attendance at virtual Special Meeting on December 30, 2020 Meeting will address reincorporation of POAI in Nevada Reincorporation expected to save POAI approximately $158,000 annually in state taxes Shareholders…
-
MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Shines Spotlight on Innovative Media in Exclusive Interview
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, was recently featured in an exclusive audio interview with NetworkNewsWire. During the…
-
Predictive Oncology (NASDAQ: POAI) Leverages Precision Medicine Expertise to Support Oncologists, Improve Patient Outcomes
Precision medicine is emerging approach to disease prevention, treatment that incorporates individual’s distinctive characteristics. New approach allows doctors, researchers to predict more accurately which treatments may work better. Helomics’ database, largest of its kind, is…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial